PE20221271A1 - Moleculas de fusion del ecd de siglec-9 y metodos de uso de estas - Google Patents

Moleculas de fusion del ecd de siglec-9 y metodos de uso de estas

Info

Publication number
PE20221271A1
PE20221271A1 PE2022000710A PE2022000710A PE20221271A1 PE 20221271 A1 PE20221271 A1 PE 20221271A1 PE 2022000710 A PE2022000710 A PE 2022000710A PE 2022000710 A PE2022000710 A PE 2022000710A PE 20221271 A1 PE20221271 A1 PE 20221271A1
Authority
PE
Peru
Prior art keywords
siglec
domain
methods
fusion molecules
ecd fusion
Prior art date
Application number
PE2022000710A
Other languages
English (en)
Inventor
Spencer Liang
Samuel Nalle
Jeonghoon Sun
Hua Long
Rashmi Bankoti
Original Assignee
Alector Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alector Llc filed Critical Alector Llc
Publication of PE20221271A1 publication Critical patent/PE20221271A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4726—Lectins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Recrystallisation Techniques (AREA)
  • External Artificial Organs (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

SE REFIERE A UN POLIPEPTIDO QUE COMPRENDE UN DOMINIO EXTRACELULAR (ECD) SIGLEC-9 QUE COMPRENDE EL DOMINIO SIGLEC-9 IGV QUE COMPRENDE UNA SECUENCIA DE AMINOACIDOS SELECCIONADA DE LAS SEQ ID NO: 109-137 Y 214-226, UN DOMINIO C2 TIPO 1 (C2T1) Y UN DOMINIO C2 TIPO 2 (C2T2); DONDE EL POLIPEPTIDO COMPRENDE UNA SECUENCIA DE AMINOACIDOS SELECCIONADA DE LAS SEQ ID NO: 79-107 Y 194-206. DICHO POLIPEPTIDO BLOQUEA LA UNION CELULAR DE UNO O MAS MIEMBROS DE LA FAMILIA SIGLEC SELECCIONADOS DE SIGLEC-3, SIGLEC-5, SIGLEC-7, SIGLEC-9, SIGLEC-10 Y SIGLEC-15. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA UTIL EN EL TRATAMIENTO DE CANCER.
PE2022000710A 2019-11-04 2020-11-03 Moleculas de fusion del ecd de siglec-9 y metodos de uso de estas PE20221271A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962930227P 2019-11-04 2019-11-04
US202063014940P 2020-04-24 2020-04-24
US202063092753P 2020-10-16 2020-10-16
PCT/US2020/058687 WO2021091885A2 (en) 2019-11-04 2020-11-03 Siglec-9 ecd fusion molecules and methods of use thereof

Publications (1)

Publication Number Publication Date
PE20221271A1 true PE20221271A1 (es) 2022-09-01

Family

ID=73598983

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2022000710A PE20221271A1 (es) 2019-11-04 2020-11-03 Moleculas de fusion del ecd de siglec-9 y metodos de uso de estas

Country Status (17)

Country Link
US (2) US11987612B2 (es)
EP (1) EP4055031A2 (es)
JP (1) JP2022553571A (es)
KR (1) KR20220092918A (es)
CN (1) CN114667298A (es)
AU (1) AU2020378251A1 (es)
BR (1) BR112022008321A2 (es)
CA (1) CA3155345A1 (es)
CL (1) CL2022001130A1 (es)
CO (1) CO2022005587A2 (es)
CR (1) CR20220244A (es)
EC (1) ECSP22044316A (es)
IL (1) IL292499A (es)
MX (1) MX2022005376A (es)
PE (1) PE20221271A1 (es)
TW (1) TW202132329A (es)
WO (1) WO2021091885A2 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021261524A1 (en) 2020-04-24 2022-11-24 Bayer Aktiengesellschaft Substituted aminothiazoles as dgkzeta inhibitors for immune activation
WO2024102635A1 (en) * 2022-11-07 2024-05-16 Alector Llc Uses of siglec-9 ecd fusion molecules in cancer treatment

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
DE3675588D1 (de) 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US6133426A (en) 1997-02-21 2000-10-17 Genentech, Inc. Humanized anti-IL-8 monoclonal antibodies
AU2003301882A1 (en) 2002-11-01 2004-06-07 The Regents Of The University Of Colorado, A Body Corporate Quantitative analysis of protein isoforms using matrix-assisted laser desorption/ionization time of flight mass spectrometry
CA3018525C (en) 2005-07-01 2023-08-01 E. R. Squibb & Sons, L.L.C. Human monoclonal antibodies to programmed death ligand 1 (pd-l1)
GB0521991D0 (en) 2005-10-28 2005-12-07 Univ Dundee Siglec-9 binding agents
US20070244038A1 (en) 2006-04-12 2007-10-18 The Regents Of The University Of California Methods for treating lymphocyte-associated disorders by modulation of siglec activity
WO2012145493A1 (en) 2011-04-20 2012-10-26 Amplimmune, Inc. Antibodies and other molecules that bind b7-h1 and pd-1
CN103987405B (zh) 2011-11-28 2017-03-29 默克专利股份公司 抗pd‑l1抗体及其用途
EA032985B1 (ru) 2011-12-21 2019-08-30 Амген Инк. Варианты полипептидов fc-pol с улучшенным связыванием неонатального рецептора fc
EP2937088B1 (en) 2012-12-21 2020-11-18 Tokushima University Composition having tissue repairing activity and utilization thereof
WO2014120642A1 (en) 2013-01-30 2014-08-07 The General Hospital Corporation Diagnosis and treatment of hepatorenal syndrome
AU2015314316B2 (en) 2014-09-10 2020-12-10 Innate Pharma Cross reactive Siglec antibodies
WO2016178996A1 (en) 2015-05-01 2016-11-10 The Regents Of The University Of California Glycan-dependent immunotherapeutic molecules
WO2017075432A2 (en) * 2015-10-29 2017-05-04 Alector Llc Anti-siglec-9 antibodies and methods of use thereof
WO2017075342A1 (en) 2015-10-30 2017-05-04 Hach Company Storage stable standards for aqueous chlorine analysis
AU2016354924A1 (en) 2015-11-17 2018-06-21 Innate Pharma Siglec-10 antibodies
CA3011092A1 (en) 2016-01-12 2017-07-20 Palleon Pharmaceuticals Inc. Use of siglec-7 or siglec-9 antibodies for the treatment of cancer
AU2017230850B2 (en) 2016-03-08 2024-04-18 Innate Pharma Siglec neutralizing antibodies
WO2018006066A1 (en) 2016-07-01 2018-01-04 The Board Of Trustees Of The Leland Stanford Junior University Inhibitory immune receptor inhibition methods and compositions
GB201611535D0 (en) 2016-07-01 2016-08-17 King S College London Methods and compositions for treating cancer with siglec-9 activity modulators
JP2020527144A (ja) 2017-07-10 2020-09-03 イナート・ファルマ・ソシエテ・アノニムＩｎｎａｔｅ Ｐｈａｒｍａ Ｐｈａｒｍａ Ｓ．Ａ． 癌を処置するためのヒトｓｉｇｌｅｃ−９に対する抗体およびヒトｎｋｇ２ａに対する抗体を使用する組み合わせ療法
JP7293188B2 (ja) 2017-07-10 2023-06-19 イナート・ファルマ・ソシエテ・アノニム Ｓｉｇｌｅｃ－９中和抗体
US20210395333A1 (en) 2018-06-07 2021-12-23 Palleon Pharmaceuticals Inc. Multimeric proteins for detecting a carbohydrate and/or treating a siglec-mediated disorder
BR112020026386A2 (pt) 2018-06-29 2021-03-30 Verseau Therapeutics, Inc. Composições e métodos para modulação de fenótipos inflamatórios com monócitos e macrófagos e usos de imunoterapia dos mesmos
CN112805032A (zh) 2018-10-02 2021-05-14 台湾浩鼎生技股份有限公司 与治疗性肿瘤学药剂组合使用抗ssea-4抗体的组合疗法
US20220211831A1 (en) 2019-04-17 2022-07-07 Bar-Ilan University Siglec-based chimeric polypeptides and uses thereof
TW202110890A (zh) 2019-06-04 2021-03-16 美商維西歐製藥公司 抗siglec-9組合物及其用於調節骨髓細胞發炎表型之方法及用途
WO2021011377A2 (en) 2019-07-12 2021-01-21 The Board Of Trustees Of The Leland Stanford Junior University Methods of enhancing immunogenicity of cancers

Also Published As

Publication number Publication date
WO2021091885A3 (en) 2021-06-17
JP2022553571A (ja) 2022-12-23
CR20220244A (es) 2022-06-28
CL2022001130A1 (es) 2023-02-24
WO2021091885A2 (en) 2021-05-14
EP4055031A2 (en) 2022-09-14
TW202132329A (zh) 2021-09-01
CA3155345A1 (en) 2021-05-14
CO2022005587A2 (es) 2022-07-29
AU2020378251A1 (en) 2022-05-26
CN114667298A (zh) 2022-06-24
KR20220092918A (ko) 2022-07-04
ECSP22044316A (es) 2022-07-29
US20240279305A1 (en) 2024-08-22
BR112022008321A2 (pt) 2022-07-26
US20210284710A1 (en) 2021-09-16
IL292499A (en) 2022-06-01
MX2022005376A (es) 2022-05-19
US11987612B2 (en) 2024-05-21

Similar Documents

Publication Publication Date Title
ES2542853T3 (es) Método para tratar miastenia grave
CL2022001271A1 (es) Agonista del receptor glp-1 y uso de este
CL2022000036A1 (es) Polipéptidos modificados y usos de los mismos (divisional de solicitud no. 201900261)
PE20190335A1 (es) Receptores de celulas t
AR111362A1 (es) Anticuerpos anti-ilt4 y fragmentos de unión a antígeno
CL2017002345A1 (es) Un nuevo complejo que comprende un péptido de penetración celular, una molécula cargo y un agonista peptídico de tlr
AR100888A1 (es) Derivados de exendina-4 como agonistas selectivos del receptor de glucagón
PE20221271A1 (es) Moleculas de fusion del ecd de siglec-9 y metodos de uso de estas
AR115418A1 (es) ANTICUERPOS ANTI-SIRPA (PROTEÍNA REGULADORA DE SEÑALES a) Y MÉTODOS DE USO DE LOS MISMOS
GT201000148A (es) Anticuerpos antimesotelina y usos de los mismos
AR113455A1 (es) Proteínas inmunomoduladoras de variantes del ligando de icos y composiciones y métodos relacionados
PE20140673A1 (es) Nuevos moduladores y metodos para su uso
PE20170471A1 (es) Polipeptidos receptores formulados y metodos relacionados
PE20190743A1 (es) Metodos para el tratamiento de la atrofia muscular y enfermedad osea con el uso de proteinas trap hibridas novedosas del ligando actriib
CR20120026A (es) Construcciones novedosas de proteína del virus de papiloma humano (hpv) y su uso en la prevención de la enfermedad por el hpv
BR112019023071A2 (pt) proteínas de fusão do receptor tgf-beta do tipo ii e uso das mesmas
PE20170503A1 (es) Proteinas de fusion de interleucina 2/receptor de interleucina-2 alfa y metodos de uso
PE20130738A1 (es) Dominios variables simples de inmunoglobulina anti-vegf
PE20081686A1 (es) Proteinas de fusion que comprenden un antigeno prame (dage)
CU20120116A7 (es) Polipéptidos que se enlazan a dr5 humana con efectos agonistas, que comprenden uno o más monómeros de un único dominio variable, utiles en el tratamiento de enfermedades y trastornos asociados con dr5
AR070134A1 (es) Agonistas de plexind1 que comprende un fragmento de semaforina 3e(sema3e) y su uso
BR112018000660A2 (pt) peptídeos anti-inflamatórios e seu uso
CL2017003097A1 (es) Composiciones y métodos para el tratamiento de la enfermedad celiaca
PE20200514A1 (es) Compuestos de mic-1 y usos de estos
PE20170955A1 (es) Nuevas proteinas inhibidoras de insectos